Danaher Co. (NYSE:DHR) Shares Bought by Leavell Investment Management Inc.

Leavell Investment Management Inc. boosted its holdings in shares of Danaher Co. (NYSE:DHR) by 12.3% in the second quarter, HoldingsChannel reports. The firm owned 9,951 shares of the conglomerate’s stock after buying an additional 1,086 shares during the period. Leavell Investment Management Inc.’s holdings in Danaher were worth $2,489,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DHR. ST Germain D J Co. Inc. grew its stake in Danaher by 1.4% during the 1st quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock valued at $719,000 after acquiring an additional 41 shares in the last quarter. Godsey & Gibb Inc. grew its stake in Danaher by 3.0% during the 1st quarter. Godsey & Gibb Inc. now owns 1,442 shares of the conglomerate’s stock valued at $360,000 after acquiring an additional 42 shares in the last quarter. Nicholas Hoffman & Company LLC. boosted its holdings in Danaher by 2.3% in the 4th quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock valued at $439,000 after purchasing an additional 43 shares during the last quarter. Los Angeles Capital Management LLC boosted its holdings in Danaher by 1.3% in the 4th quarter. Los Angeles Capital Management LLC now owns 3,470 shares of the conglomerate’s stock valued at $803,000 after purchasing an additional 43 shares during the last quarter. Finally, Berger Financial Group Inc boosted its holdings in Danaher by 1.7% in the 4th quarter. Berger Financial Group Inc now owns 2,517 shares of the conglomerate’s stock valued at $582,000 after purchasing an additional 43 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have weighed in on DHR shares. Robert W. Baird boosted their target price on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Stifel Nicolaus boosted their target price on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. TD Cowen boosted their target price on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Finally, Royal Bank of Canada upped their price objective on shares of Danaher from $297.00 to $300.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Six research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $276.88.

Danaher Stock Up 0.4 %

Shares of NYSE:DHR traded up $1.16 during trading hours on Thursday, reaching $269.24. The stock had a trading volume of 1,653,536 shares, compared to its average volume of 2,869,823. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70. The firm’s 50 day moving average is $257.54 and its 200-day moving average is $253.09. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The stock has a market capitalization of $199.42 billion, a price-to-earnings ratio of 45.44, a P/E/G ratio of 4.62 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the firm posted $2.05 EPS. The company’s quarterly revenue was down 2.9% compared to the same quarter last year. Research analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Insider Activity at Danaher

In related news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now owns 29,407 shares in the company, valued at approximately $8,229,254.88. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The disclosure for this sale can be found here. Insiders have sold 38,707 shares of company stock valued at $10,786,944 in the last ninety days. Insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.